How I treat refractory and early relapsed acute myeloid leukemia - PubMed (original) (raw)
Review
. 2015 Jul 16;126(3):319-27.
doi: 10.1182/blood-2014-10-551911. Epub 2015 Apr 7.
Affiliations
- PMID: 25852056
- DOI: 10.1182/blood-2014-10-551911
Free article
Review
How I treat refractory and early relapsed acute myeloid leukemia
Felicitas Thol et al. Blood. 2015.
Free article
Abstract
Between 10% and 40% of newly diagnosed patients with acute myeloid leukemia (AML) do not achieve complete remission with intensive induction therapy and are therefore categorized as primary refractory or resistant. Few of these patients can be cured with conventional salvage therapy. They need to be evaluated regarding eligibility for allogeneic hematopoietic stem cell transplantation (HSCT) as this is currently the treatment with the highest probability of cure. To reduce the leukemia burden prior to transplantation, salvage chemotherapy regimens need to be employed. Whenever possible, refractory/relapsed patients should be enrolled in clinical trials as we do not have highly effective and standardized treatments for this situation. Novel therapies include tyrosine kinase inhibitors, small-molecule inhibitors (e.g., for Polo-like kinase 1 and aminopeptidase), inhibitors of mutated isocitrate dehydrogenase (IDH) 1 and IDH2, antibody-based therapies, and cell-based therapies. Although the majority of these therapies are still under evaluation, they are likely to enter clinical practice rapidly as a bridge to transplant and/or in older, unfit patients who are not candidates for allogeneic HSCT. In this review, we describe our approach to refractory/early relapsed AML, and we discuss treatment options for patients with regard to different clinical conditions and molecular profiles.
© 2015 by The American Society of Hematology.
Similar articles
- Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure.
Wattad M, Weber D, Döhner K, Krauter J, Gaidzik VI, Paschka P, Heuser M, Thol F, Kindler T, Lübbert M, Salih HR, Kündgen A, Horst HA, Brossart P, Götze K, Nachbaur D, Köhne CH, Ringhoffer M, Wulf G, Held G, Salwender H, Benner A, Ganser A, Döhner H, Schlenk RF. Wattad M, et al. Leukemia. 2017 Jun;31(6):1306-1313. doi: 10.1038/leu.2017.23. Epub 2017 Jan 19. Leukemia. 2017. PMID: 28138160 - Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
Bose P, Vachhani P, Cortes JE. Bose P, et al. Curr Treat Options Oncol. 2017 Mar;18(3):17. doi: 10.1007/s11864-017-0456-2. Curr Treat Options Oncol. 2017. PMID: 28286924 Review. - Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia.
Cui L, Liu Y, Pang Y, Qian T, Quan L, Cheng Z, Dai Y, Ye X, Pang Y, Shi J, Ke X, Wu D, Fu L. Cui L, et al. Cancer Gene Ther. 2020 Feb;27(1-2):1-14. doi: 10.1038/s41417-019-0119-5. Epub 2019 Jul 11. Cancer Gene Ther. 2020. PMID: 31292516 Review. - Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.
Zhang C, Lam SSY, Leung GMK, Tsui SP, Yang N, Ng NKL, Ip HW, Au CH, Chan TL, Ma ESK, Yip SF, Lee HKK, Lau JSM, Luk TH, Li W, Kwong YL, Leung AYH. Zhang C, et al. Cancer. 2020 Jan 15;126(2):344-353. doi: 10.1002/cncr.32534. Epub 2019 Oct 3. Cancer. 2020. PMID: 31580501 Clinical Trial. - Association of fludarabin, cytarabine, and fractioned gemtuzumab followed by hematopoietic stem cell transplantation for first-line refractory acute myeloid leukemia in children: A single-center experience.
Penel-Page M, Plesa A, Girard S, Marceau-Renaut A, Renard C, Bertrand Y. Penel-Page M, et al. Pediatr Blood Cancer. 2020 Jun;67(6):e28305. doi: 10.1002/pbc.28305. Epub 2020 Apr 19. Pediatr Blood Cancer. 2020. PMID: 32307866 Clinical Trial.
Cited by
- Allogeneic Stem Cell Transplantation in Refractory Acute Myeloid Leukaemia.
Bono R, Sapienza G, Tringali S, Rotolo C, Patti C, Mulè A, Calafiore V, Santoro A, Castagna L. Bono R, et al. Cells. 2024 Apr 26;13(9):755. doi: 10.3390/cells13090755. Cells. 2024. PMID: 38727291 Free PMC article. Review. - Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study.
Li YY, Ge SS, Huang YH, Xu MZ, Wan CL, Tan KW, Tao T, Zhou HX, Xue SL, Dai HP. Li YY, et al. Blood Cancer J. 2024 Jan 18;14(1):12. doi: 10.1038/s41408-024-00982-3. Blood Cancer J. 2024. PMID: 38238305 Free PMC article. No abstract available. - Integrated Analysis of Single-Cell RNA-Seq and Bulk RNA-Seq Unravels the Molecular Feature of Tumor-Associated Macrophage of Acute Myeloid Leukemia.
Gao X. Gao X. Genet Res (Camb). 2024 Jan 2;2024:5539065. doi: 10.1155/2024/5539065. eCollection 2024. Genet Res (Camb). 2024. PMID: 38205232 Free PMC article. - Exploring the Potential of siRNA Delivery in Acute Myeloid Leukemia for Therapeutic Silencing.
Ubeda Gutierrez AM, Remant Bahadur KC, Brandwein J, Uludağ H. Ubeda Gutierrez AM, et al. Nanomaterials (Basel). 2023 Dec 18;13(24):3167. doi: 10.3390/nano13243167. Nanomaterials (Basel). 2023. PMID: 38133064 Free PMC article. - Chidamide, Decitabine, Cytarabine, Aclarubicin, and Granulocyte Colony-stimulating Factor Therapy for Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Study from a Single-Center.
Kong FC, Qi L, Zhou YL, Yu M, Huang WF, Li F. Kong FC, et al. Curr Med Sci. 2023 Dec;43(6):1151-1161. doi: 10.1007/s11596-023-2805-7. Epub 2023 Dec 7. Curr Med Sci. 2023. PMID: 38057538
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous